Traws Pharma
TRAW
8 hedge funds and large institutions have $4.36M invested in Traws Pharma in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
11% less funds holding
Funds holding: 9 → 8 (-1)
24% less capital invested
Capital invested by funds: $5.71M → $4.36M (-$1.35M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$124K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$114K |
| 3 |
VF
Virtu Financial
New York
|
+$62.1K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$31K |
| 5 |
Renaissance Technologies
New York
|
+$10.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$114K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$36K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10.3K |
| 4 |
HFM
Hartford Financial Management
Hartford,
Connecticut
|
-$3K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCP
1
Tyndall Capital Partners
New York
| $1.71M | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $1.44M | +$114K | +11 | +8% |
|
|
6CM
3
683 Capital Management
New York
| $641K | +$124K | +12 | +22% |
|
|
4
Renaissance Technologies
New York
| $206K | +$10.3K | +1 | +5% |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $155K | – | – | – |
|
|
BC
6
Boxer Capital
San Diego,
California
| $92K | -$114K | -11 | -20% |
|
|
PAM
7
Panagora Asset Management
Boston,
Massachusetts
| $67K | +$31K | +3 | +75% |
|
|
VF
8
Virtu Financial
New York
| $55K | +$62.1K | +6 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $1K | -$10.3K | -1 | Closed |
|
10
BlackRock
New York
| $1K | – | – | – |
|
11
Citigroup
New York
| $1K | – | – | – |
|
|
BCM
12
Bridgeway Capital Management
Houston,
Texas
| – | -$36K | -3 | Closed |
|
|
13
Creative Planning
Overland Park,
Kansas
| – | -$1K | – | – |
|
|
HFM
14
Hartford Financial Management
Hartford,
Connecticut
| – | -$3K | – | – |
|
|
IA
15
IFP Advisors
Tampa,
Florida
| – | -$1K | – | – |
|
TRAW Hedge Fund Activity: Q3 2017 in Review
8 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2017, worth a combined $4.36M — down 24% from $5.71M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of TRAW and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.
The largest buyer was 683 Capital Management, adding an estimated $124K. The largest seller was Boxer Capital, cutting an estimated $114K.
- 8 institutional investors held Traws Pharma (TRAW) as of Q3 2017, down from 9 in Q2 2017.
- Funds reported $4.36M of Traws Pharma stock for Q3 2017, down 24% quarter-over-quarter.
- 1 fund opened new Traws Pharma positions in Q3 2017 and 2 closed out, a net change of -1 holder.
- The largest Traws Pharma buyer in Q3 2017 was 683 Capital Management, an estimated $124K added.
- The largest Traws Pharma seller in Q3 2017 was Boxer Capital, an estimated $114K sold.
Based on aggregated 13F filings for Q3 2017.